The impacts of Chinese drug volume-based procurement policy on the volume and expenditure of antibiotic drugs

Ying Yang
Wuhan University

Lei Chen
Wuhan University

Xinfeng Ke
Wuhan University

Zongfu Mao (zfmao@whu.edu.cn)
Wuhan University

Bo Zheng
Peking University First Hospital

Research Article

Keywords: National Centralized Drug Procurement (NCDP) policy, "4+7", volume-based procurement, antibiotic use, China

Posted Date: January 9th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-143454/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at BMC Health Services Research on July 8th, 2021. See the published version at https://doi.org/10.1186/s12913-021-06698-5.
Abstract

Background: In 2019, Chinese government implemented the first round of National Centralized Drug Procurement (NCDP) pilot (so-called "4+7" policy) in mainland China, in which an oral antibiotic agent (cefuroxime axetil) was included. Given the current condition of the irrational use of antibiotics in China, this study aims to evaluate the potential effect of the "4+7" policy on antibiotic use.

Methods: This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. Oral antibiotic drugs related to "4+7" policy were selected as study samples, including cefuroxime axetil and its alternative drugs. Segmented linear regression analysis with interrupted time series was adopted to examine the effect of "4+7" policy on the volume and expenditure of antibiotic drugs.

Results: Compared with April to December 2018, the total volume and expenditures of cefuroxime axetil and its alternative antibiotic drugs from April to December 2019 increased 41.8% and 18.1%, respectively. The results of segmented linear regression showed that the volume of cefuroxime axetil products significantly increased 161.16 thousand DDDs after "4+7" policy (95% CI: 59.43 to 262.90, p-value = 0.004). For the alternative drugs of cefuroxime axetil, the volume and expenditures significantly increased 273.65 thousand DDDs (95% CI: 90.17 to 457.12, p-value = 0.006) and 3471.66 thousand RMB (95% CI: 1529.70 to 5413.62, p-value = 0.001), respectively.

Conclusion: This study provides evidence that the implementation of "4+7" volume-based procurement policy was associated with significant increases in the volume and expenditure of cefuroxime axetil and its alternative drugs. The increase in antibiotic use after the policy needs special attention and vigilance.

Background

The overuse and misuse of antibiotics stimulated the more rapid emergence of antibiotic resistant bacteria and antibiotic resistant genes, reducing their therapeutic potential against human and animal pathogens [1,2]. The rising of antibiotic resistant levels, in combination with a lack of new effective antibiotics, increases the morbidity and mortality of infectious diseases, as well as driving inflation related to healthcare costs [3]. World Health Organization (WHO) characterized antimicrobial resistance as a global public health crisis that must be managed with the utmost urgency [4].

China is one of the world's largest producers and consumers of antibiotics [5]. 92,700 tonnes of antibiotics (inclusive of 36 antibiotics) were consumed in China in 2013, which is estimated exceed usage in the UK and much of northern Europe (normalized by the defined daily dose), by a factor of six [6]. Globally, 76% of the overall increase in antibiotic consumption between 2000 and 2010 was attributable to BRICS countries (Brazil, Russia, India, China, and South Africa) [7]. In BRICS countries, up to 57% of the increase of antibiotic use in the hospital sector was attributable to China [7]. Yin et al. [8] systematically reviewed the condition of antibiotic utilization in China by using the data of 556,435 outpatient encounters, and reported an overall percentage of 50.3% for outpatients prescribed antibiotics,
of which, 74.0% were prescribed one antibiotic, 23.3% were prescribed two antibiotics and 2.0% were prescribed three or more antibiotics. A national survey showed that 52.9% of the patients visiting primary care institutions in China were prescribed antibiotics, but only 39.4% of those who received antibiotics needed them based on their clinical condition [9]. Generally, China has a high prescription use of antibiotics for both inpatients and outpatients [10]. As a result of antibiotic misuse, China has the highest level of antibiotic resistance and the most rapid growth of antibiotic resistance globally [11,12]. Besides, the direct cost associated with the overuse of antibiotics in China is estimated to be around 2.91 to 13.93 billion yuan ($0.42 to 2.02 billion USD) per year [13]. Therefore, the overuse of antibiotics is an important issue that needs to be vigilant in China.

In January 2019, the General Office of the State Council of the People's Republic of China issued the National Centralized Drug Procurement (NCDP) policy, aiming at deepening the health system reform and improving the mechanism for the formation of drug prices [14]. In the first round of NCDP pilot, 11 cities were selected as pilot cities to carry out drug volume-based purchasing, including 4 municipalities (Beijing, Tianjin, Shanghai, and Chongqing) and 7 key cities (Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi’an) in mainland China. Therefore, the first round of NCDP is also known as the "4+7" pilot or "4+7" policy in mainland China. The highlight of the "4+7" policy lies in the implementation of "volume-based procurement", which refers to that the tenderer (government representative) clarifies the procurement volume (60-70% of the total annual drug use of all public medical institutions in pilot cities) when conducting tendering, and the tenderers (pharmaceutical companies) quote according to this specific procurement volume. "4+7" policy successfully tendered 25 drug varieties, and most of whom are drugs for chronic diseases such as hypertension, diabetes, and hyperlipidemia [15]. The average price of 25 selected drugs dropped 52%, with a maximum drop of 96%. It is worth noting that, an oral antibiotic drug, i.e. cefuroxime axetil was included in the 25 drugs. According to the bidding results, cefuroxime axetil tablets (250mg*12 tablets/box) manufactured by Chengdu Brilliant Pharmaceutical Co. Ltd won the bidding at a price of 6.16 yuan/box, which dropped 52.5% when compared with the average price in the past three years.

According to the characteristics of the "4+7" policy, the clinical use of the bid winning antibiotic drug is constrained by the "contracted procurement volume", that is, the hospitals are required to complete their reported annual procurement volume. The usage of winning cefuroxime axetil was included in the performance evaluation of hospitals, clinical departments, and even doctors. Therefore, we proposed that there might be potential risk for the overuse of antibiotic drugs related to cefuroxime axetil after the implementation of "4+7" policy. However, no qualitative evidence clarified this issue. However, there was no relevant research clarified the impact of volume-based procurement on the utilization of antibiotic drugs. It is urgent to provide quantitative evidence regarding this issue.

Given the shortage of existing evidence, we conducted this exploratory study to quantitatively evaluate the effect of "4+7" policy on the utilization and expenditures of antibiotic drugs, considering the case of cefuroxime axetil and its alternative drugs.
Methods

Data sources

This study used data from Centralized Drug Procurement Survey in Shenzhen 2019 (CDPS-SZ 2019). In China, the CDPS-SZ 2019 was organized and conducted by the Global Health Institute of Wuhan University between December 2019 and January 2020. The survey aimed to evaluate the effect of drug-related policies in Shenzhen, and collected monthly drug purchase order data between 2017 and 2019. In the CDPS-SZ 2019 database, each purchase order record included purchase date, generic name, dosage form, specification, pharmaceutical manufacturer, price per unit, purchase volume, purchase expenditures, etc. A general database containing 963,127 monthly aggregated purchase order records was established, involving 1079 drug varieties (by generic name), 346 medical institutions, 857 pharmaceutical manufacturers. The total purchase expenditures reached 20.87 billion RMB.

This study aims to examine the effect of "4+7" policy on the utilization of policy-related oral antibiotic agents. Thus, we included samples with the following criteria: (a) the medication covered cefuroxime axetil and its alternative drugs, (b) the time period is between January 2018 and December 2019, and (c) the medical institutions purchasing drugs were from Shenzhen. Finally, 9577 purchase order records of 30 drug varieties (by generic name) were extracted, involving 70 medical institutions, 30 pharmaceutical manufacturers.

Outcome measures

This study assessed the effect of "4+7" policy on both volume and expenditures of antibacterial agents. Expenditure data was reported in Chinese yuan, i.e. RMB. Volume was measured using Defined Daily Dose (DDD), a measurement developed by WHO to compare drug consumptions. DDD refers to the average maintenance dose per day for a drug used for its main indication in adults. In this study, DDD value of each medication is determined according to the *Guidelines for ATC classification and DDD assignment 2020* [16]. DDD equivalence per package (DPP) of medicines was calculated in DDD units (DPP = unit strength × pack size/DDD) [17]. The total volume for each group of procured medicines (DDDs) was estimated as the summed DPPs of all-inclusive products.

$$ DDDs = \sum_{i=1}^{n} (DPP_i \times N_i) $$

Where, $N_i$ represents the number of packages of a certain product ($i$) delivered to the medical institutions.

Statistical analysis
Descriptive statistics were used. We first described the volume and expenditures of included medications in the same period before (April to December 2018) and after (April to December 2019) the implementation of "4+7" policy. Then, we created graphical displays of the monthly procurement volume and expenditures of each study medication in order to observe and describe patterns over time from January 2018 to December 2019.

Interrupted time-series (ITS) analysis was applied to assess the effect of "4+7" policy on purchase volume and expenditures of Cefuroxime Axetil and related medications. ITS is a commonly used approach for evaluating changes in longitudinal series following a quasi-experimental intervention occurring at a fixed point in time, such as the date of implementing "4+7" policy, i.e. 1 April 2019 in Shenzhen. We constructed interrupted time series using drug procurement data in Shenzhen from January 2018 to December 2019. The time unit was set to 1 month and the intervention time point was set to April 2019, making 24 time points available for analysis, including 15 points before the intervention and 9 points thereafter. To estimate the effect of the intervention on the outcome variables, the following segmented linear regression model was developed [18]:

\[
Y_t = \beta_0 + \beta_1 \times time_t + \beta_2 \times intervention_t + \beta_3 \times time \text{ after intervention}_t + \beta_4 \times cold + \epsilon_t
\]

Where, \( Y_t \) is the independent outcome variable (volume or expenditures) in month \( t \); \( time \) is a continuous variable indicating time in months at time \( t \) from the start of the observation period; \( intervention \) is an indicator for time \( t \) occurring before (\( intervention = 0 \)) or after (\( intervention = 1 \)) "4+7" policy, which was implemented at month 15 in the series; and \( time \text{ after intervention} \) is a continuous variable indicating months passed since the intervention (time prior to the intervention is coded 0). Besides, we set a dummy variable \( cold \) to control the extreme value of antibiotic use during the Spring Festival holiday, which is “wild data points” in this study [18]. It is when the Spring Festival that is the coldest time of the year in China, and common seasonal illness (cold) prevalence. The possibility of antibiotics overuse rises to treat fever and other associated symptoms [19-21]. The variable \( cold \) is assigned the value 1 in December and January of each year and 0 otherwise.

In this model, \( \beta_0 \) estimates the baseline level of the independent variable at the beginning of the observation period. \( \beta_1 \) estimates the linear trend during the preintervention period where time \( t \) is an integer variable indicating the time in months at time \( t \) from the beginning of the study period. \( \beta_2 \) estimates the change in the outcome immediately following the intervention. \( \beta_3 \) estimates the change in trend in the outcome measures after the intervention compared with the monthly trend before the intervention. \( \beta_4 \) estimates the "coldest weather" effect. \( \epsilon_t \) is an estimate of the random error at time \( t \). Durbin-Watson test was performed to test the presence of first-order auto-correlation (a value around 2 indicates no sign of auto-correlation). If auto-correlation is detected, the Prais-Winsten
method was applied to estimate the regression. Stata version 16.0 was used to perform the ITS analysis.

Results

Descriptive statistics

A total of 30 drug varieties (by generic name) were included in this study. The total purchase volume was 29.33 million DDDs, and the total purchase expenditure was 266.83 million RMB. Of those, the volume and expenditures of cefuroxime axetil were 6.39 million DDDs and 12.74 million RMB, respectively.

Table 1 demonstrates the change of volume and expenditures of antibiotic medications included in this study during the same period before (April to December 2018) and after (April to December 2019) the implementation of "4+7" policy. Compared with April to December 2018, the purchase volume of cefuroxime axetil during April to December 2019 increased by 92.9%, and the purchase expenditures decreased by 18.9%. Of which, the volume and expenditures of winning products increased by 182.9% and 102.4%, respectively; those of non-winning products decreased by 70.3% and 74.1%, respectively. From April to December 2019, the volume and expenditures of cefuroxime axetil's alternative medication increased by 30.2% and 20.1%, respectively, when compared with those from April to December 2018. Besides, the overall volume of all included antibiotics in this study rose 41.8% and the expenditures rose 18.8%.

ITS analysis

Changes of winning and non-winning products

The monthly trends of volume and expenditures of winning and non-winning cefuroxime axetil products are displayed in Figure 1. Table 2 and Table 3 show the results of the segmented regression analysis of winning and non-winning products. For volume, winning products significantly increased 185.07 thousand DDDs after "4+7" policy (95% CI: 80.13 to 290.02, p-value = 0.002). The trend of volume decreased by 0.82 thousand DDDs per month but with no statistically significant (p-value = 0.920). Non-winning products decreased by 26.35 thousand DDDs (p-value = 0.096) and the trend of volume decreased by 4.27 thousand DDDs per month (p-value = 0.091), but no significant differences were observed. As for expenditures, winning products significantly increased 158.92 thousand RMB after "4+7" policy (95% CI: 57.34 to 260.50, p-value = 0.004).

Changes of cefuroxime axetil and alternative drugs

The monthly trends of volume and expenditures of cefuroxime axetil and its alternative drugs are displayed in Figure 2. Table 4 and Table 5 show the results of the segmented regression analysis of
cefuroxime axetil and its alternative drugs. For volume, cefuroxime axetil significantly increased 161.16 thousand DDDs after "4+7" policy (95% CI: 59.43 to 262.90, p-value = 0.004). The trend of cefuroxime axetil's volume decreased by 5.41 thousand DDDs per month but with no statistically significant (p-value = 0.480). The alternatives drugs of cefuroxime axetil significantly increased by 273.65 thousand DDDs after "4+7" policy (95% CI: 90.17 to 457.12, p-value = 0.006). The trend of alternatives drugs' volume significantly decreased by 47.57 thousand DDDs per month (95% CI: -74.59 to -20.25, p-value = 0.002). The total volume of selected antibiotic drugs significantly increased 436.31 thousand DDDs after "4+7" policy (95% CI: 190.81 to 681.81, p-value = 0.001). The trend of volume significantly decreased by 54.09 thousand DDDs per month (95% CI: 90.31 to 17.88, p-value = 0.006).

In terms of expenditures, the alternatives drugs of cefuroxime axetil significantly increased 3471.66 thousand RMB after "4+7" policy (95% CI: 1529.70 to 5413.62, p-value = 0.001). The trend of alternatives drugs' expenditures significantly decreased by 658.52 thousand RMB per month (95% CI: -944.20 to -372.83, p-value <0.001). The total expenditures of selected antibiotic drugs significantly increased 3437.80 thousand RMB after "4+7" policy (95% CI: 1324.56 to 5551.05, p-value = 0.003). The trend expenditures significantly decreased by 680.44 thousand RMB per month (95% CI: -991.63 to -369.25, p-value <0.001).

**Discussion**

In this study, using the drug purchase order data of medical institutions in Shenzhen between January 2018 and December 2019, we analyzed the impact of "4+7" volume-based procurement policy on the utilization and expenditures of cefuroxime axetil and its related antibiotic drugs by conducting interruption time series analysis. The present findings might provide references for promoting the rational use of antibiotic agents, as well as the implementation and adjustment of NCDP policy in the following rounds.

This study found that the purchase volume and expenditures of winning cefuroxime axetil products significantly increased in Shenzhen after the implementation of "4+7" policy, with an increment of 182.9% and 102.4%, respectively. The finding is generally consistent with the results of all 25 winning drugs regarding the total purchase volumes and expenditures [22]. It is suggested that after a price cut of 52.5% for the bid winning products, the medication accessibility was improved for patients, and the medication demand was greatly released [23]. This fully reflects the notable effect of the 4+7 policy in reducing the drug burden of the public. However, the results of segmented linear regression showed no significant difference in the monthly trend of the volume and expenditures of the winning cefuroxime axetil product before and after "4+7" policy. On the one hand, it indicated that the effect of "4+7" policy might be insufficient for failing to change the prescription behavior of doctors, so it does not change the changing trend of antibiotic use. On the other hand, it may be related to the short post-intervention time period applied in this study (only 9 months after the intervention), thus is deficiencies in trend analysis. In the future, it is necessary for follow-up research to explore this problem. In the future, it might make sense to conduct continuous tracking analysis and to explore the long-term trend of policy impact.
Compared with April to December 2018, the volume and expenditures of non-winning cefuroxime axetil products from April to December 2019 decreased by 70.3% and 74.1%, respectively. However, the results of segmented linear regression indicated no statically significant difference in the change of volume or expenditure for non-winning products, whether in level change or in trend change. In terms of the original intention of policy design, the NCDP policy hopes that the bid winning drugs under substantial price cut will replace the non-winning drugs as much as possible, so as to archive the goal of reducing drug costs and relieve the overall drug burden of patients [24,25]. From this point of view, the original intention of this policy may have not been fully achieved.

In this study, the total volume of all cefuroxime axetil products significantly increased after the intervention, with an increase of 92.9% compared with the same period in 2018. More importantly, the results of segmented linear regression showed that the volume and expenditures of cefuroxime axetil's alternative drugs increased significantly after "4+7" policy, which increased by 31.2% and 21.0%, respectively. Overall, significant increasements were also observed in the total volume and expenditures of all included antibiotic agents in this study, with an increment of 41.8% for volume and 18.8% for expenditures. These findings suggested that the risk of overuse of antibiotics might be exacerbated after the "4+7" volume-based procurement. Li et al [26] found that patients’ average drug costs had not been brought down by the price reduction after in implementation of bidding procurement of antimicrobial drugs in Hubei, China. Liu et al.’s survey [27] on 5 county-level public hospitals in Anhui, China reported that the daily drug costs (DDDc) of antibacterial drugs decreased after the implementation of centralized bidding system, while the volumes and expenditures were still increasing. These findings are generally in line with our results in this study, indicating that price cut alone could not effectively curb the increasing trend of antibiotic drugs whether in volume or in expenditures. More importantly, it is necessary to change doctors' behaviors regarding the prescription of antibiotics [19], so as to promote the rational use of antibiotics and control the growth of drug expenditures.

The results of segmented linear regression also found that monthly trend of the volume and expenditures of cefuroxime axetil’s alternative drugs significantly decreased by 54.09 thousand DDDs per month and 680.44 thousand RMB per month, respectively. Besides, the monthly trend of total volume and expenditures for all included antibiotic agents in this study also significantly slowed down. On the one hand, it might reflect the effectiveness of a series of supporting policies issued by the Chinese government regarding drug use monitoring in medical institutions on the management of antibiotic use [28]. On the other hand, this result might be related to the short post-intervention time period used in this study, thus is deficiencies in trend analysis. Following studies are needed to focus on a longer post-intervention time period and control possible confounding factors, such as policies that might affect the use of antibiotic drugs, so as to further analyze the long-term effect of volume-based procurement policy on antibiotic use.

Overall, the increase in the volume and expenditures of bid winning products is a common phenomenon for most kinds of drugs under "4+7" policy [22,29]. This is so-called "bypass effect" and very common in pharmaceutical policies [30,31], that is, the expenditure of the drugs with price cuts was steady or
decrease, but the use of drugs without price cuts substantially increased. For antibiotic drugs, their overuse is of great hazard [32]. Thus, we believe there is a certain possibility that antibiotic drugs might not be suitable for involving in volume-based procurement policy. In the future, it is necessary to furtherly improve the contents of the DCNP policy, such as standardizing the formulation criteria of drug procurement catalogue. In addition, policy supporting measures for NCDP policy should be implemented, such as promoting the adoption of prescriptions audit on policy-related antibiotic drugs.

Several potential limitations should be mentioned regarding the present study. Firstly, in terms of evaluating policy effect, the two groups of ITS has more advantages than the single group ITS by setting a control group [33]. However, we failed to set a control group in this study, thus it is difficult to observe and control other factors that may affect the results. Secondly, considering the policy intervention time point and the stability of baseline data, this study only included the data for 24 months. The follow-up periods were short from the date when the policy was implemented with only 9 time points after the intervention, which may be insufficient in trend analysis.

**Conclusion**

This study provides evidence that the implementation of "4+7" volume-based procurement policy was associated with significant increases in the volume and expenditure of cefuroxime axetil and its alternative drugs. Given the increasing antibiotic resistance in China, the rising of antibiotic use after the policy needs special attention and vigilance. For the improvement of DCNP policy, it might make great sense to standardizing the formulation criteria of drug procurement catalogue and to promote the adoption of prescriptions audit on policy-related drugs.

**Abbreviations**

WHO: World Health Organization; BRICS countries: Brazil, Russia, India, China, and South Africa; NCDP: National Centralized Drug Procurement; CDPS-SZ: Centralized Drug Procurement Survey in Shenzhen; DDD: Defined Daily Dose; DPP: DDD equivalence per package; ITS: Interrupted time-series; CI: Confidence interval; DDDc: Daily Drug Costs.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of Faculty of Medical Sciences, Wuhan University (IRB number: 2019YF2050). In this project, no actual human participants were recruited, and no consent to participant was necessary.

**Consent for publication**
Availability of data and materials

The datasets generated or analysed during the current study are not publicly available due confidentiality policies but are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Global Health Institute, Wuhan University, China. The role of funding body included designing the study, analysis and interpretation of data, and writing the manuscript.

Authors' contributions

ZM and BZ designed the study. YY and LC collected data. YY, LC, and XK analyzed and interpreted the data. YY, LC and XK drafted the manuscript. ZM and BZ supervised the study and critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Authors' information

1 School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China. 2Global Health Institute, Wuhan University, 115# Donghu Road, Wuhan 430071, China. 3Institute of Clinical Pharmacology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.

References

1 Wright GD. Antibiotic resistance in the environment: a link to the clinic? CURR OPIN MICROBIOL. 2010;13(5):589-94. doi: 10.1016/j.mib.2010.08.005.
2 Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC INFECT DIS. 2014;14:13. doi: 10.1186/1471-2334-14-13.

3 Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N et al. Antibiotic resistance—the need for global solutions. LANCET INFECT DIS. 2013;13(12):1057-98. doi: 10.1016/S1473-3099(13)70318-9.

4 WHO. Global action Plan on Antimicrobial Resistance. 2015. https://www.who.int/phi/implementation/Marc_Sprenger_WHO.pdf. Accessed 25 Dec 2020.

5 Qiao M, Ying G, Singer AC, Zhu Y. Review of antibiotic resistance in China and its environment. ENVIRON INT. 2018;110:160-72. doi: 10.1016/j.envint.2017.10.016.

6 Zhang QQ, Ying GG, Pan CG, Liu YS, Zhao JL. Comprehensive evaluation of antibiotics emission and fate in the river basins of China: source analysis, multimedia modeling, and linkage to bacterial resistance. ENVIRON SCI TECHNOL. 2015;49(11):6772-82. doi: 10.1021/acs.est.5b00729.

7 Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. The Lancet Infectious Diseases. 2014;14(8):742-50. doi: 10.1016/S1473-3099(14)70780-7.

8 Yin X, Song F, Gong Y, Tu X, Wang Y, Cao S et al. A systematic review of antibiotic utilization in China. J ANTIMICROB CHEMOTH. 2013;68(11):2445-52. doi: 10.1093/jac/dkt223.

9 Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary health care settings in China. JAMA INTERN MED. 2014;174(12):1914-20. doi: 10.1001/jamainternmed.2014.5214.

10 Kan Q, Wen J, Liu X, Li Z. Inappropriate use of antibiotics in children in China. The Lancet. 2016;387(10025):1273-4. doi: 10.1016/S0140-6736(16)30019-8.

11 Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health. 2006;2:6. doi: 10.1186/1744-8603-2-6.

12 Heddini A, Cars O, Qiang S, Tomson G. Antibiotic resistance in China—a major future challenge. The Lancet. 2009;373(9657):30. doi: https://doi.org/10.1016/S0140-6736(08)61956-X.

13 Xiao Y, Hou F, Wang J, Yan Q, Sun Z, Lv X et al. An investigation into socio-economic impact of adverse drug reactions of antibacterial agent irrational use. Chinese Health Economics. 2010;29(05):94-6. doi: 10.3969/j.issn.1003-0743.2010.05.034.

14 General Office of the State Council. Notice on Issuing National Drug Centralized Purchasing and Using Pilot. 2019. http://www.gov.cn/zhuanti/2019-01/17/content_5358604.htm. Accessed 25 Dec 2020.
15 Joint Purchasing Office. The results of 4+7 city drug centralized procurement. 2018. http://www.smpaa.cn/gjsdcg/2018/12/07/8531.shtml. Accessed 25 Nov 2020.

16 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2020, Norway. 2019. http://www.whocc.no. Accessed 20 Nov 2020.

17 World Health Organization. ATC/DDD Index 2020. 2019. https://www.whocc.no/atc_ddd_index/. Accessed 23 Dec 2020.

18 Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J CLIN PHARM THER. 2002;27(4):299-309. doi: 10.1046/j.1365-2710.2002.00430.x.

19 Zhen L, Jin C, Xu HN. The impact of prescriptions audit and feedback for antibiotic use in rural clinics: interrupted time series with segmented regression analysis. BMC HEALTH SERV RES. 2018;18(1):777. doi: 10.1186/s12913-018-3602-z.

20 Li Z, Wu B, Hu M, Guo C, Chen L, Jin C. The impact of a peer review and feedback intervention on antibiotic prescribing: Interrupted time series analysis at village clinics in Qingdao, Shandong Province. Chinese Journal of Health Policy. 2013;6(10):54-9. doi: 10.3969/j.issn.1674-2982.2013.10.010.

21 Chen M, Wang Q, Shen H. Analysis on seasonal change rule of antibiotic use in our hospital. China Pharmaceuticals. 2012;21(01):52-3. doi: 10.3969/j.issn.1006-4931.2012.01.031.

22 Mao Z, Yang Y, Chen L. Reform of Drug Supply and Guarantee System in China: Policy Measures and Effects. In: Chinese Academy of Medical Sciences, editors. Development Report on Health Reform in China (2020). Beijing: Social Sciences Academic Press; 2020.

23 People's Daily. The price of medicine has been reduced and the burden has been lightened. http://society.people.com.cn/n1/2020/0110/c1008-31542162.html. Accessed 15 Sep 2020.

24 Mao Z, Chen L, Yang Y. Great changes in the pharmaceutical industry. China Health. 2019(11):82-4

25 Tang M, He J, Chen M, Cong L, Xu Y, Yang Y et al. "4+7" city drug volume-based purchasing and using pilot program in China and its impact. Drug Discoveries & Therapeutics. 2019;13(6):365-9. doi: 10.5582/ddt.2019.01093.

26 Li R, Zhang X, Song J. Effect of Bidding of Antimicrobial Drugs on Hospital Drugs Consumption. China Pharmacy. 2009;20(1):1-4

27 Liu J, Yang D, Zhang J. Effect of the centerized bidding system of drug on the use of antibacterials in five country public hospitals in Anhui Province. Journal of Bengbu Medical College. 2016;41(4):527-30. doi: 10.13898/j.cnki.issn.1000-2200.2016.04.033.
28 General Office of the State Council. Opinions on strengthening the performance appraisal of tertiary public hospitals. 2019. http://www.gov.cn/zhengce/content/2019-01/30/content_5362266.htm. Accessed 10 Sep 2020.

29 Hao M, Wang H, Luo N, Jiang B. The normalization system of national centralized purchasing is gradually mature and clear. China Health. 2020(06):79-81. doi: 10.15973/j.cnki.cn11-3708/d.2020.06.023.

30 Kwon H, Bae S, Choi S, Park S, Lee E, Park S et al. Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea. HEALTH POLICY. 2019;123(4):388-92. doi: 10.1016/j.healthpol.2018.11.002.

31 Kwon H, Hong J, Godman B, Yang B. Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents. HEALTH POLICY. 2013;112(3):217-26. doi: 10.1016/j.healthpol.2013.08.011.

32 Zhen X, Lundborg CS, Sun X, Hu X, Dong H. The Clinical and Economic Impact of Antibiotic Resistance in China: A Systematic Review and Meta-Analysis. Antibiotics (Basel, Switzerland). 2019;8(3):115. doi: 10.3390/antibiotics8030115.

33 Yang L, Shicheng Y, Chenggang J, Mengjie Y, Xuejun M, Qiqi W. Design and analysis of two groups interrupt time series. Chinese Journal of Epidemiology. 2019;40(9):1159-63. doi: 10.3760/cma.j.issn.0254-6450.2019.09.027.

**Tables**

**Table 1.** Purchase volume and expenditures of included antibacterial agents in April to December 2018 and April to December 2019.

| Categories      | Volume (million DDDs) | Expenditures (million RMB) |
|-----------------|-----------------------|----------------------------|
|                 | Apr. to Dec. 2018     | Apr. to Dec. 2019 | Relative change (%) | Apr. to Dec. 2018 | Apr. to Dec. 2019 | Relative change (%) |
| Cefuroxime Axetil | 1.75                  | 3.38                | 92.9                | 5.19             | 4.21              | -18.9               |
| Winning products | 1.13                  | 3.20                | 182.9               | 1.62             | 3.29              | 102.4               |
| Non-winning products | 0.62              | 0.18                | -70.3               | 3.56             | 0.92              | -74.1               |
| Alternatives    | 7.71                  | 10.04               | 30.2                | 87.49            | 105.89            | 21.0                |
| Total           | 9.47                  | 13.42               | 41.8                | 92.67            | 110.09            | 18.8                |

**Table 2.** Results of the segmented linear regression models for the volume of winning and non-winning products.
Table 3. Results of the segmented linear regression models for the expenditures of winning and non-winning products.

| Model 1, Winning products | Coefficient | Standard Error | t | p-value | 95% CI Lower | 95% CI Upper |
|---------------------------|-------------|----------------|---|---------|--------------|--------------|
| Secular trend, $\beta_1$  | 3.94        | 3.28           | 1.20 | 0.245   | -2.92        | 10.80        |
| Change in level, $\beta_2$ | 185.07     | 50.14          | 3.69 | 0.002   | 80.13        | 290.02       |
| Change in trend, $\beta_3$ | -0.82      | 8.01           | -1.00 | 0.920   | -17.58       | 15.95        |
| Cold, $\beta_4$           | 73.25       | 31.36          | 2.34 | 0.031   | 7.61         | 138.89       |
| Constant, $\beta_0$       | 87.74       | 30.10          | 2.92 | 0.009   | 24.75        | 150.73       |

Model 1, $F = 25.18$, p-value < 0.001, $R^2 = 0.841$, Adjusted $R^2 = 0.808$; Model 2, $F = 13.02$, p-value < 0.001, $R^2 = 0.733$, Adjusted $R^2 = 0.676$.

| Model 2, Non-winning products | Coefficient | Standard Error | t | p-value | 95% CI Lower | 95% CI Upper |
|-------------------------------|-------------|----------------|---|---------|--------------|--------------|
| Secular trend, $\beta_1$      | 0.33        | 0.98           | 0.33 | 0.744   | -1.73        | 2.38         |
| Change in level, $\beta_2$    | -26.35      | 15.03          | -1.75 | 0.096   | -57.81       | 5.11         |
| Change in trend, $\beta_3$    | -4.27       | 2.40           | -1.78 | 0.091   | -9.30        | 0.75         |
| Cold, $\beta_4$               | 23.97       | 9.41           | 2.55 | 0.020   | 4.27         | 43.66        |
| Constant, $\beta_0$           | 59.08       | 9.02           | 6.55 | 0.000   | 40.21        | 77.95        |

Model 1, $F = 20.02$, p-value < 0.001, $R^2 = 0.808$, Adjusted $R^2 = 0.768$; Model 2, $F = 14.17$, p-value < 0.001, $R^2 = 0.749$, Adjusted $R^2 = 0.696$.

Table 4. Results of the segmented linear regression models for the volume of Cefuroxime Axetil and its alternative agents.
| Model 1, Cefuroxime Axetil | Coefficient | Standard Error | t | p-value | 95% CI Lower | 95% CI Upper |
|----------------------------|-------------|----------------|---|---------|---------------|---------------|
| Secular trend, $\beta_1$   | 4.12        | 3.09           | 1.33 | 0.199   | -2.35         | 10.59         |
| Change in level, $\beta_2$ | 161.16      | 48.61          | 3.32 | 0.004   | 59.43         | 262.90        |
| Change in trend, $\beta_3$ | -5.41       | 7.52           | -0.72 | 0.480   | -21.16        | 10.33         |
| Cold, $\beta_4$            | 89.67       | 32.04          | 2.80 | 0.011   | 22.62         | 156.72        |
| Constant, $\beta_0$        | 149.22      | 28.04          | 5.32 | 0.000   | 90.54         | 207.89        |

| Model 2, Alternatives      | Coefficient | Standard Error | t | p-value | 95% CI Lower | 95% CI Upper |
|----------------------------|-------------|----------------|---|---------|---------------|---------------|
| Secular trend, $\beta_1$   | 20.52       | 5.42           | 3.79 | 0.001   | 9.18          | 31.86         |
| Change in level, $\beta_2$ | 273.65      | 87.66          | 3.12 | 0.006   | 90.17         | 457.12        |
| Change in trend, $\beta_3$ | -47.57      | 12.91          | -3.69 | 0.002   | -74.59        | -20.55        |
| Cold, $\beta_4$            | 313.94      | 65.63          | 4.78 | 0.000   | 176.56        | 451.31        |
| Constant, $\beta_0$        | 634.46      | 47.66          | 13.31 | 0.000   | 534.70        | 734.22        |

| Model 3, Total             | Coefficient | Standard Error | t | p-value | 95% CI Lower | 95% CI Upper |
|----------------------------|-------------|----------------|---|---------|---------------|---------------|
| Secular trend, $\beta_1$   | 24.70       | 7.25           | 3.41 | 0.003   | 9.52          | 39.88         |
| Change in level, $\beta_2$ | 436.31      | 117.29         | 3.72 | 0.001   | 190.81        | 681.81        |
| Change in trend, $\beta_3$ | -54.09      | 17.30          | -3.13 | 0.006   | -90.31        | -17.88        |
| Cold, $\beta_4$            | 385.09      | 87.21          | 4.42 | 0.000   | 202.55        | 567.63        |
| Constant, $\beta_0$        | 786.20      | 63.89          | 12.30 | 0.000   | 652.47        | 919.94        |

Model 1, $F = 19.63$, p-value < 0.001, $R^2 = 0.805$, Adjusted $R^2 = 0.764$; Model 2, $F = 32.63$, p-value < 0.001, $R^2 = 0.873$, Adjusted $R^2 = 0.846$; Model 3, $F = 36.12$, p-value < 0.001, $R^2 = 0.884$, Adjusted $R^2 = 0.859$.

**Table 5.** Results of the segmented linear regression models for the expenditures of Cefuroxime Axetil and its alternative agents.
|                      | Coefficient | Standard Error | t   | p-value | 95% CI | Lower | Upper |
|----------------------|-------------|----------------|-----|---------|--------|-------|-------|
| **Model 1, Cefuroxime Axetil** |             |                |     |         |        |       |       |
| Secular trend, $\beta_1$ | 4.96        | 5.92           | 0.84| 0.412   | -7.43  | 17.35 |
| Change in level, $\beta_2$ | -28.45      | 93.99          | -0.30| 0.765   | -225.17| 168.27|
| Change in trend, $\beta_3$ | -22.85      | 14.37          | -1.59| 0.128   | -52.93 | 7.22  |
| Cold, $\beta_4$ | 221.88      | 63.49          | 3.49| 0.002   | 88.99  | 354.77|
| Constant, $\beta_0$ | 486.16      | 53.39          | 9.11| 0.000   | 374.42 | 597.90|
| **Model 2, Alternatives** |             |                |     |         |        |       |       |
| Secular trend, $\beta_1$ | 168.83      | 57.35          | 2.94| 0.008   | 48.79  | 288.86|
| Change in level, $\beta_2$ | 3471.66     | 927.83         | 3.74| 0.001   | 1529.70| 5413.62|
| Change in trend, $\beta_3$ | -658.52     | 136.49         | -4.82| 0.000   | -944.20| -372.83|
| Cold, $\beta_4$ | 3630.32      | 697.27         | 5.21| 0.000   | 2170.91| 5089.72|
| Constant, $\beta_0$ | 7813.30      | 504.01         | 15.50| 0.000   | 6758.39| 8868.22|
| **Model 3, Total** |             |                |     |         |        |       |       |
| Secular trend, $\beta_1$ | 173.62       | 62.41          | 2.78| 0.012   | 43.00  | 304.24|
| Change in level, $\beta_2$ | 3437.80      | 1009.66        | 3.40| 0.003   | 1324.56| 5551.05|
| Change in trend, $\beta_3$ | -680.44     | 148.68         | -4.58| 0.000   | -991.63| -369.25|
| Cold, $\beta_4$ | 3839.38       | 755.78         | 5.08| 0.000   | 2257.51| 5421.26|
| Constant, $\beta_0$ | 8304.29      | 549.01         | 15.13| 0.000   | 7155.20| 9453.38|

Model 1, $F = 5.04$, $p$-value $= 0.006$, $R^2 = 0.515$, Adjusted $R^2 = 0.413$; Model 2, $F = 26.85$, $p$-value $< 0.001$, $R^2 = 0.850$, Adjusted $R^2 = 0.818$; Model 3, $F = 23.22$, $p$-value $< 0.001$, $R^2 = 0.830$, Adjusted $R^2 = 0.795$.

Figures
Figure 1

Trends of monthly drug purchase volume and expenditures for winning and non-winning products. (a) Volume (thousand DDDs); (b) Expenditures (thousand RMB).
Figure 2

Trends of monthly drug purchase volume and expenditures for Cefuroxime Axetil and its Alternatives. (a) Volume (thousand DDDs); (b) Expenditures (thousand RMB).